Truist Securities Maintains Buy on Treace Medical Concepts, Lowers Price Target to $30
Portfolio Pulse from jenniferd'souza@benzinga.com
Truist Securities analyst Richard Newitter maintains a 'Buy' rating on Treace Medical Concepts (NASDAQ:TMCI) but has lowered the price target from $33 to $30.
August 09, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained a 'Buy' rating on Treace Medical Concepts but lowered the price target from $33 to $30.
The news is directly related to Treace Medical Concepts (TMCI). While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term price. However, the impact is neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100